Disruption of tRNA threonylation triggers RIG-I mediated anti-tumour immune response.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41735308.
- Also identified by DOI 10.1038/s41467-026-69964-2 and PMC identifier 13043769.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Tumour-induced mechanisms of immune evasion hinder immune response to cancer, particularly in melanoma. mRNA translation, by ensuring accurate protein synthesis, regulates cancer phenotypes and immune response, but the underlying mechanisms remain unclear. Here, we reveal how O-sialoglycoprotein endopeptidase (OSGEP), catalysing the tRNA modification N<sup>6</sup>-threonylcarbamoyladenosine (t<sup>6</sup>A), drives protein homeostasis in cancer cells to maintain T-cell exclusion and prevent anti-tumour immune response. t<sup>6</sup>A-deficient melanoma cells disrupt efficient cytoplasmic translation of ANN codons (trinucleotides with A in the first position and N = any nucleotide), causing specific protein aggregation and the formation of integrated stress response-dependent stress granules. We discovered that OSGEP loss triggers melanoma regression by relocating RIG-I to stress granules, leading to its pathway activation. As a result, T-cells are recruited to the tumour site and orchestrate an anti-tumour immune response. Finally, an OSGEP-driven gene signature in melanoma patients is associated with T-cell infiltration and improved overall survival. Together, our findings position t<sup>6</sup>A tRNA modification as a promising therapeutic target for melanoma treatment.
Medical subject headings
- RNA, Transfer
- Melanoma
- DEAD Box Protein 58